SGIOF
SHIONOGI & CO LTD$18.00 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $18.00
1 year
−0.6%
from $18.11 · Oct 27
30 days
+9.8%
from $16.39
52-week range
$15.21–26.00
−31% from high · low Dec 4
Avg volume 20D
40
Oct 5 spike 300
Short interest
4.94M
−6.5%
Filing reports
1
analyzed by SecBot
SecBot read BULLISH 1 report · latest
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 1/1
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E Apr 6 Gov. contract: $119M govt contract: SHIONOGI INC
- E Jul 30 Trial readout: Results Pending: Redasemtide (Phase 2) — Completed 45d ago
- X Jul 31 Short interest jumps 28.9% to 5.74M
- E Aug 10 Trial readout: Results Pending: Redasemtide (Phase 2) — Completed 56d ago
- E Aug 11 Trial readout: Results Pending: Redasemtide (Phase 2) — Completed 57d ago
- E Aug 25 Trial readout: Results Pending: Redasemtide (Phase 2) — Completed 71d ago
- E Sep 8 Trial readout: Results Pending: Redasemtide (Phase 2) — Completed 85d ago
- E Oct 19 Trial readout: T-90d Trial Readout: Sivopixant (Phase 2)
Signal stack
Where each data set points today.
- Short sellersSTEADY
Short interest −6.5% to 4.94M shares.
- TrendUPTREND
1% above its 50-day average.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 25, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
May 29, 2026 Event
Apr 6, 2026 SEC Market Event
Original Approval — Type 1 - New Molecular Entity
Shionogi Inc. secured a $119.16 million contract from the Department of Health and Human Services for the late-stage…
GOVT-CONTRACT — Impact 5/10
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Sep 30, 20264,944,260
shares short
-6.5%
vs prior settlement
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 25, 2026
Trial readout
🔒 Fresh data, subscribers only
Oct 21, 2026
Clinical Trial
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
Phase 3 · TERMINATED
Oct 18, 2026
Trial readout
T-90d Trial Readout: Sivopixant (Phase 2)
Trial: Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea Sponsor: Shionogi Phase: Phase 2 | Status…
Oct 12, 2026
Trial readout
T-90d Trial Readout: Sivopixant (Phase 2)
Trial: Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea Sponsor: Shionogi Phase: Phase 2 | Status…
Oct 7, 2026
Clinical Trial
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
Phase 3 · COMPLETED
SecBot reports
1 filing · 1 bullish · 0 bearishAll SGIOF filing & press-release reports (1)
- GOVT-CONTRACT reportApr 6, 2026